English | 简体中文 | 繁體中文 | 한국어 | 日本語
Tuesday, 31 October 2023, 07:00 HKT/SGT
Share:
    

Source: Molekule Consulting
Dr. Daniel Pascheles Rejoins Molekule Consulting as Strategic Advisor

MIAMI, FL, Oct 31, 2023 - (ACN Newswire) - In a significant development that promises to shape the future of Molekule Consulting, we are thrilled to announce the return of Dr. Daniel Pascheles as a Strategic Advisor.

Dr. Pascheles, with an illustrious career spanning over 30 years in the biopharmaceutical competitive and strategic intelligence sector, is poised to bring a wealth of knowledge and expertise to Molekule. His previous roles include leading Competitive Intelligence & Strategy functions at industry leaders Merck & Co./MSD and Aventis, in addition to serving as CEO of Molekule Consulting.

"Dr. Pascheles' return-to-Molekule marks a thrilling, new chapter in our shared story. His homecoming is not just a reunion, but a renewal of our mutual commitment to excellence and innovation. Welcome back, Dr. Pascheles!" expressed David Alderman, President & CEO at Molekule Consulting.

In his pivotal role as Strategic Advisor, Dr. Pascheles will employ his vast industry expertise and strategic prowess to shape and foster Molekule's trajectory of growth and value journey into the future.

"I am thrilled to be back!" remarked Dr. Pascheles. "It is with great excitement that I rejoin the dynamic and growing team at Molekule, and I eagerly anticipate contributing to the company's ongoing success."

For further details on this exciting development, please contact David Alderman at dalderman@molekuleconsulting.com; +1 305.504.3030.

About Molekule Consulting:

Molekule Consulting provides best-in-class strategic intelligence and is solely dedicated to the biopharma sector. We shape the path forward with our strategic intelligence, driving transformative changes across the biopharmaceutical landscape.

Our purpose is clear: to provide high-impact, actionable insights that catalyze growth and foster innovation for biopharmaceutical brands, franchises, and businesses. Our clientele encompasses industry titans, robust mid-sized companies, and ambitious newcomers within the global biopharmaceutical realm.

Interested in learning more about Molekule Consulting's biopharmaceutical-focused strategies and market intelligence? Dive deeper here: www.molekuleconsulting.com

Contact Information

David Alderman, President & CEO, dalderman@molekuleconsulting.com +1 305.504.3030



Topic: Press release summary
Source: Molekule Consulting

Sectors: Daily Finance
https://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

Latest Press Releases
GMG Reaches Market Commercialisation Milestone on Energy Savings Coating THERMAL-XR(R)  
Nov 24, 2024 23:54 HKT/SGT
New Progress in the Merger of Guotai Junan and Haitong Securities  
Nov 24, 2024 18:14 HKT/SGT
CleverTap Recognized as a 'Strong Performer' in the Cross-Channel Marketing Hubs, Q4 2024 Report  
Nov 23, 2024 20:42 HKT/SGT
First Quarterly Profit, High-Quality Platform Growth, NaaS Technology Accelerates Ecosystem Development  
Nov 22, 2024 23:22 HKT/SGT
Tat Hong Equipment Service Co., Ltd. Announces 2024/25 Interim Results  
Nov 22, 2024 19:56 HKT/SGT
Daeshin MC Co., Ltd. Unveils Its Clean Solutions Creating Pleasant Indoor Environments from Industrial Sites to Public Facilities  
Nov 22, 2024 11:00 HKT/SGT
Kaplan Fox & Kilsheimer LLP Alerts Investors to a Securities Class Action Against Humacyte, Inc. (HUMA) - Deadline is January 17, 2025  
Friday, November 22, 2024 10:00:00 AM
Jacobson Pharma Announces FY2025 Interim Results  
Nov 22, 2024 10:00 HKT/SGT
NaaS Q3 2024 Recap: Strategic Shifts and Tech Innovations for Growth  
Thursday, November 21, 2024 9:59:00 PM
GMG Unveils SUPER G(R): A Game-Changing Graphene Solution for the Lithium-Ion Battery Industry  
Nov 21, 2024 21:29 HKT/SGT
More Press release >>
 Events:
More events >>
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575